Jianping Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jianping Zhou has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
Ming Dong
Department of Gastrointestinal Surgery & Hernia and Abdominal Wall Surgery, The First Hospital of China Medical University, Shenyang, China
17 shared publicationsGang Liu
Department of Gastrointestinal Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, People’s Republic of China
14 shared publicationsJingtong Tang
Department of Gastrointestinal Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, People’s Republic of China
11 shared publicationsWeiwei Sheng
Department of Gastrointestinal Surgery, The First Hospital, China Medical University, Shenyang 110001, Liaoning, China
9 shared publicationsXin Li
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
9 shared publicationsJian Sun
Department of Gastrointestinal Surgery & Hernia and Abdominal Wall Surgery, the First Hospital, China Medical University, Shenyang, China
7 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Springer Nature in BMC Surgery
Effect of inferior mesenteric and left colic artery sheath resection on long-term left colic artery patency: a randomized controlled pilot trial
Objective: To evaluate whether resection of the inferior mesenteric artery (IMA) and left colic artery (LCA) perivascular sheath, while preserving the LCA, affects postoperative LCA patency and perioperative outcomes in minimally invasive radical rectal cancer surgery. Methods: In this single-center randomized controlled pilot trial (registration number: ChiCTR2200063479), 60 patients were assigned 1:1 to sheath resection (experimental group, n = 30) or sheath preservation (control group, n = 30). The prespecified primary endpoint was LCA patency at 6 months; 12- and 24-month patency assessments were exploratory. Continuous and categorical outcomes were compared using Welch’s t test, the Mann-Whitney U test, the Pearson chi-square test, or an exact test, as appropriate. Follow-up imaging was analyzed on an available-case basis. Results: The experimental group had a higher lymph-node yield (17.17 ± 5.07 vs. 13.13 ± 4.76; mean difference, 4.03; 95% CI, 1.49–6.57; P = 0.002) and fewer patients with < 12 retrieved nodes (4/30 [13.3%] vs. 12/30 [40.0%]; P = 0.020). Time to first flatus was longer after sheath resection (median, 3.0 vs. 2.0 days; P = 0.001), whereas operative time, blood loss, analgesic duration, bowel frequency, and complications did not differ significantly. Two patients (one per group) were lost to follow-up. At 6 months, LCA occlusion occurred in 5/29 patients (17.2%) in the experimental group and 6/29 (20.7%) in the control group (risk difference, -3.4% points; 95% CI, -23.6 to 17.0; P = 0.738). The corresponding proportions in the experimental and control groups were 8/29 (27.6%) and 10/29 (34.5%) at 12 months ( P = 0.570), and 11/29 (37.9%) and 16/29 (55.2%) at 24 months ( P = 0.188). Conclusion: In this pilot trial, perivascular sheath resection was not associated with a statistically significant increase in LCA occlusion through 24 months and was associated with a higher lymph-node yield. However, the patency estimates were imprecise; the nonsignificant differences should not be interpreted as proof of equivalence or non-inferiority. The longer time to first flatus also warrants consideration. Trial registration: Chinese Clinical Trial Registry (ChiCTR2200063479), registered on 8 September 2022. Retrospectively registered.
- 13 November 2026
- Published by Springer Nature in BMC Surgery
Open AccessEffect of inferior mesenteric and left colic artery sheath resection on long-term left colic artery patency: a randomized controlled pilot trial
Objective: To evaluate whether resection of the inferior mesenteric artery (IMA) and left colic artery (LCA) perivascular sheath, while preserving the LCA, affects postoperative LCA patency and perioperative outcomes in minimally invasive radical rectal cancer surgery. Methods: In this single-center randomized controlled pilot trial (registration number: ChiCTR2200063479), 60 patients were assigned 1:1 to sheath resection (experimental group, n = 30) or sheath preservation (control group, n = 30). The prespecified primary endpoint was LCA patency at 6 months; 12- and 24-month patency assessments were exploratory. Continuous and categorical outcomes were compared using Welch’s t test, the Mann-Whitney U test, the Pearson chi-square test, or an exact test, as appropriate. Follow-up imaging was analyzed on an available-case basis. Results: The experimental group had a higher lymph-node yield (17.17 ± 5.07 vs. 13.13 ± 4.76; mean difference, 4.03; 95% CI, 1.49–6.57; P = 0.002) and fewer patients with < 12 retrieved nodes (4/30 [13.3%] vs. 12/30 [40.0%]; P = 0.020). Time to first flatus was longer after sheath resection (median, 3.0 vs. 2.0 days; P = 0.001), whereas operative time, blood loss, analgesic duration, bowel frequency, and complications did not differ significantly. Two patients (one per group) were lost to follow-up. At 6 months, LCA occlusion occurred in 5/29 patients (17.2%) in the experimental group and 6/29 (20.7%) in the control group (risk difference, -3.4% points; 95% CI, -23.6 to 17.0; P = 0.738). The corresponding proportions in the experimental and control groups were 8/29 (27.6%) and 10/29 (34.5%) at 12 months ( P = 0.570), and 11/29 (37.9%) and 16/29 (55.2%) at 24 months ( P = 0.188). Conclusion: In this pilot trial, perivascular sheath resection was not associated with a statistically significant increase in LCA occlusion through 24 months and was associated with a higher lymph-node yield. However, the patency estimates were imprecise; the nonsignificant differences should not be interpreted as proof of equivalence or non-inferiority. The longer time to first flatus also warrants consideration. Trial registration: Chinese Clinical Trial Registry (ChiCTR2200063479), registered on 8 September 2022. Retrospectively registered.
- Open Access
- 1 October 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-22
Nanotechnology-Enabled Immunotherapy for Colorectal Cancer: Overcoming the "Cold” Tumor Microenvironment in Microsatellite-Stable Disease
Background: Immune checkpoint inhibitors (ICIs) have transformed the management of mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC), yet the ~95% of patients with mismatch repair-proficient/microsatellite-stable (pMMR/MSS) disease derive little benefit owing to an immunologically "cold” tumor microenvironment (TME), poor T-cell infiltration, myeloid dominance, TGF-β–enriched stroma, and the systemically immunosuppressive milieu imposed by hepatic metastases. Clinically tested combinations—multikinase inhibitor plus anti–PD-1, Fc-enhanced dual checkpoint blockade, chemotherapy– or antiangiogenic–ICI regimens—have so far produced modest, largely non-durable response rates that are further attenuated in liver-metastatic disease, motivating approaches that pharmacologically remodel the TME rather than only release checkpoint restraint. Objective: To provide an evidence-stratified synthesis of nanotechnology-enabled immunotherapy in CRC that explicitly separates (a) clinically established evidence, (b) strategies under early-phase clinical investigation, and (c) concepts that remain preclinical or are extrapolated from other tumor types, and to derive from this appraisal a biomarker-enriched translational research agenda. Methods: Narrative, integrative (non-systematic) review. PubMed, Embase, Web of Science, ClinicalTrials.gov, and ASCO/ESMO/AACR proceedings were searched from January 2010 through April 2026. Each strategy was appraised according to the highest available level of evidence, the tumor type and model system in which the evidence was generated, and its demonstrated CRC specificity. Results: In current clinical practice, nanomedicine in CRC is essentially limited to nanoparticle-formulated cytotoxics exploited for pharmacokinetic advantage (e.g. liposomal irinotecan), whereas nano-enabled immunotherapy is confined to a small number of early-phase trials—most notably lipid nanoparticle (LNP)–formulated individualized neoantigen mRNA vaccines in ctDNA-positive resected CRC and hafnium-oxide nanoparticle radioenhancers—none of which has yet demonstrated a progression-free or overall survival benefit in MSS CRC. Against this background we critically appraise six classes of strategy: (i) LNP-based mRNA neoantigen vaccines; (ii) polymeric and inorganic nanocarriers for STING and TLR agonists; (iii) tumor-associated macrophage–repolarizing nanoparticles; (iv) nano-radiosensitizers and photothermal/photodynamic platforms priming immunogenic cell death; (v) nano-formulated checkpoint inhibitor delivery; and (vi) locoregional nano-strategies directed at hepatic metastasis–specific immunosuppression. For categories (ii)–(vi) the supporting evidence is predominantly murine (largely subcutaneous CT26/MC38 models) or extrapolated from immunologically "hot” tumors such as melanoma and non–small-cell lung cancer, in which both the underlying biology and the checkpoint backbone differ materially from MSS CRC. Recurrent translational barriers include low, highly heterogeneous nanoparticle accumulation in human tumors, dense TGF-β–rich stroma and elevated interstitial pressure, mononuclear phagocyte system clearance, liver-metastasis–specific tolerance that subcutaneous models do not reproduce, unresolved manufacturing/CMC and regulatory pathways, and the absence of validated pharmacodynamic biomarkers of intratumoral immune conversion. Conclusion: Nanotechnology offers a mechanistically coherent and experimentally testable—but at present clinically unproven—set of strategies for converting "cold” MSS CRC into immune-responsive disease. We therefore position nano-enabled immunotherapy as a research priority rather than an imminent standard of care, and argue that its clinical value can only be established through biomarker-enriched, paired-biopsy early-phase trials with pharmacodynamic endpoints of immune conversion and prospective stratification by metastatic site (particularly hepatic involvement) and consensus molecular subtype. Limitations: This is a narrative rather than systematic review; it is therefore subject to selection and publication bias, and much of the evidence synthesized is preclinical and of limited direct translational certainty.
- 1 October 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-22
Open AccessNanotechnology-Enabled Immunotherapy for Colorectal Cancer: Overcoming the "Cold” Tumor Microenvironment in Microsatellite-Stable Disease
Background: Immune checkpoint inhibitors (ICIs) have transformed the management of mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC), yet the ~95% of patients with mismatch repair-proficient/microsatellite-stable (pMMR/MSS) disease derive little benefit owing to an immunologically "cold” tumor microenvironment (TME), poor T-cell infiltration, myeloid dominance, TGF-β–enriched stroma, and the systemically immunosuppressive milieu imposed by hepatic metastases. Clinically tested combinations—multikinase inhibitor plus anti–PD-1, Fc-enhanced dual checkpoint blockade, chemotherapy– or antiangiogenic–ICI regimens—have so far produced modest, largely non-durable response rates that are further attenuated in liver-metastatic disease, motivating approaches that pharmacologically remodel the TME rather than only release checkpoint restraint. Objective: To provide an evidence-stratified synthesis of nanotechnology-enabled immunotherapy in CRC that explicitly separates (a) clinically established evidence, (b) strategies under early-phase clinical investigation, and (c) concepts that remain preclinical or are extrapolated from other tumor types, and to derive from this appraisal a biomarker-enriched translational research agenda. Methods: Narrative, integrative (non-systematic) review. PubMed, Embase, Web of Science, ClinicalTrials.gov, and ASCO/ESMO/AACR proceedings were searched from January 2010 through April 2026. Each strategy was appraised according to the highest available level of evidence, the tumor type and model system in which the evidence was generated, and its demonstrated CRC specificity. Results: In current clinical practice, nanomedicine in CRC is essentially limited to nanoparticle-formulated cytotoxics exploited for pharmacokinetic advantage (e.g. liposomal irinotecan), whereas nano-enabled immunotherapy is confined to a small number of early-phase trials—most notably lipid nanoparticle (LNP)–formulated individualized neoantigen mRNA vaccines in ctDNA-positive resected CRC and hafnium-oxide nanoparticle radioenhancers—none of which has yet demonstrated a progression-free or overall survival benefit in MSS CRC. Against this background we critically appraise six classes of strategy: (i) LNP-based mRNA neoantigen vaccines; (ii) polymeric and inorganic nanocarriers for STING and TLR agonists; (iii) tumor-associated macrophage–repolarizing nanoparticles; (iv) nano-radiosensitizers and photothermal/photodynamic platforms priming immunogenic cell death; (v) nano-formulated checkpoint inhibitor delivery; and (vi) locoregional nano-strategies directed at hepatic metastasis–specific immunosuppression. For categories (ii)–(vi) the supporting evidence is predominantly murine (largely subcutaneous CT26/MC38 models) or extrapolated from immunologically "hot” tumors such as melanoma and non–small-cell lung cancer, in which both the underlying biology and the checkpoint backbone differ materially from MSS CRC. Recurrent translational barriers include low, highly heterogeneous nanoparticle accumulation in human tumors, dense TGF-β–rich stroma and elevated interstitial pressure, mononuclear phagocyte system clearance, liver-metastasis–specific tolerance that subcutaneous models do not reproduce, unresolved manufacturing/CMC and regulatory pathways, and the absence of validated pharmacodynamic biomarkers of intratumoral immune conversion. Conclusion: Nanotechnology offers a mechanistically coherent and experimentally testable—but at present clinically unproven—set of strategies for converting "cold” MSS CRC into immune-responsive disease. We therefore position nano-enabled immunotherapy as a research priority rather than an imminent standard of care, and argue that its clinical value can only be established through biomarker-enriched, paired-biopsy early-phase trials with pharmacodynamic endpoints of immune conversion and prospective stratification by metastatic site (particularly hepatic involvement) and consensus molecular subtype. Limitations: This is a narrative rather than systematic review; it is therefore subject to selection and publication bias, and much of the evidence synthesized is preclinical and of limited direct translational certainty.
- Open Access
- 9 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1910736
Prognostic and clinicopathological value of perineural invasion in colorectal cancer: a meta-analysis
Background: Perineural invasion (PNI) is a pathological feature associated with aggressive tumor behavior in several solid malignancies. In colorectal cancer (CRC), PNI has been reported to correlate with poorer prognosis, as well as increased risks of postoperative recurrence and metastasis. However, the available evidence regarding the prognostic significance of PNI in CRC remains limited and inconsistent. Unlike previous meta-analyses that included studies across broader time span. This study focuses on recent evidence and specifically investigates the sources of heterogeneity and its clinical significance. Therefore, this study aimed to evaluate the prognostic and clinicopathological value of PNI in CRC. Methods: The PubMed, Web of Science, Embase, and Cochrane Library databases were all thoroughly searched between January 1, 2020, and October 9, 2025.Studies included in this review comprised cohort, case–control that reported on PNI status and survival outcomes in CRC. Two reviewers independently extracted the data and evaluated the studies’ quality in accordance with PRISMA recommendations. The Newcastle–Ottawa Scale was used to evaluate the studies’ quality. By computing the hazard ratio (HR) and its 95% confidence interval (CI), the prognostic significance of PNI for CRC was evaluated. Results: A total of 9 retrospective studies were included. The pooled analysis suggested that PNI was associated with worse OS (HR = 2.23, 95%CI: 1.48-3.35, P < 0.001) and DFS (HR = 1.94, 95%CI: 1.44-2.64, P < 0.05) in patients with CRC. However, substantial heterogeneity was observed in both analyses (OS: I²=79.7%; DFS: I²=67.4%), and publication bias was suggested by Egger’s tests (OS: p=0.0097; DFS: p=0.0085). Conclusions: Based on recent studies, PNI was associated with poorer OS and DFS in CRC and may serve as a useful pathological marker for risk stratification. However, the findings should be interpreted cautiously because all included studies were retrospective and substantial heterogeneity and potential publication bias were present. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420251161522.
- 9 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1910736
Open AccessPrognostic and clinicopathological value of perineural invasion in colorectal cancer: a meta-analysis
Background: Perineural invasion (PNI) is a pathological feature associated with aggressive tumor behavior in several solid malignancies. In colorectal cancer (CRC), PNI has been reported to correlate with poorer prognosis, as well as increased risks of postoperative recurrence and metastasis. However, the available evidence regarding the prognostic significance of PNI in CRC remains limited and inconsistent. Unlike previous meta-analyses that included studies across broader time span. This study focuses on recent evidence and specifically investigates the sources of heterogeneity and its clinical significance. Therefore, this study aimed to evaluate the prognostic and clinicopathological value of PNI in CRC. Methods: The PubMed, Web of Science, Embase, and Cochrane Library databases were all thoroughly searched between January 1, 2020, and October 9, 2025.Studies included in this review comprised cohort, case–control that reported on PNI status and survival outcomes in CRC. Two reviewers independently extracted the data and evaluated the studies’ quality in accordance with PRISMA recommendations. The Newcastle–Ottawa Scale was used to evaluate the studies’ quality. By computing the hazard ratio (HR) and its 95% confidence interval (CI), the prognostic significance of PNI for CRC was evaluated. Results: A total of 9 retrospective studies were included. The pooled analysis suggested that PNI was associated with worse OS (HR = 2.23, 95%CI: 1.48-3.35, P < 0.001) and DFS (HR = 1.94, 95%CI: 1.44-2.64, P < 0.05) in patients with CRC. However, substantial heterogeneity was observed in both analyses (OS: I²=79.7%; DFS: I²=67.4%), and publication bias was suggested by Egger’s tests (OS: p=0.0097; DFS: p=0.0085). Conclusions: Based on recent studies, PNI was associated with poorer OS and DFS in CRC and may serve as a useful pathological marker for risk stratification. However, the findings should be interpreted cautiously because all included studies were retrospective and substantial heterogeneity and potential publication bias were present. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420251161522.
- Open Access
- 9 July 2026
- Published by Elsevier in SSRN Electronic Journal
Neoadjuvant Chemoradiotherapy Plus Lateral Lymph Node Dissection Improves Oncological Outcomes in Rectal Cancer with Lateral Lymph Node Metastasis: A Prospective Multicenter Cohort Study
Background: Current evidence suggests that neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME) alone is insufficient for magnetic resonance imaging (MRI)–suspected lateral lymph node metastasis (LLNM) in rectal cancer. However, whether upfront TME with lateral lymph node dissection (LLND) is adequate, and whether adding nCRT before planned LLND confers additional benefit, remains controversial.Methods: Between May 2021 and September 2022, a total of 342 patients from 20 Chinese centers were enrolled, of whom 293 were included in the final analysis and received either long-course nCRT plus TME with LLND or upfront TME+LLND. Groups were balanced by propensity score matching. The primary endpoint was 3-year recurrence-free survival (RFS).Findings: After matching, the nCRT group had significantly better 3-year RFS (HR 0.54; 95% CI. 0.32–0.92; P=0.023) and locoregional recurrence-free survival (HR 0.37; 95% CI, 0.19–0.74; P=0.005); distant metastasis-free survival did not differ (HR 0.74; 95% CI, 0.37–1.47; P=0.385). In patients with pretreatment positive lateral nodes (n=141), nCRT also improved RFS (HR 0.53; 95% CI, 0.28–0.99; P=0.049) and local control (HR 0.35; 95% CI, 0.15–0.77; P=0.010). Pathologic complete response in lateral nodes after nCRT was 44.7% (34/76). Overall postoperative complication rates were similar between groups (19.8% vs 16.0%; P=0.474), as were severe complications (grade III–V, 9.4% vs 8.5%; P=0.811).Interpretation: In MRI-suspected LLNM, adding nCRT to TME with LLND significantly improves RFS and local control without increasing morbidity. Upfront surgery alone is insufficient. These findings support a combined treatment paradigm and confirm the necessity of nCRT in these patients.
- 9 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNeoadjuvant Chemoradiotherapy Plus Lateral Lymph Node Dissection Improves Oncological Outcomes in Rectal Cancer with Lateral Lymph Node Metastasis: A Prospective Multicenter Cohort Study
Background: Current evidence suggests that neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME) alone is insufficient for magnetic resonance imaging (MRI)–suspected lateral lymph node metastasis (LLNM) in rectal cancer. However, whether upfront TME with lateral lymph node dissection (LLND) is adequate, and whether adding nCRT before planned LLND confers additional benefit, remains controversial.Methods: Between May 2021 and September 2022, a total of 342 patients from 20 Chinese centers were enrolled, of whom 293 were included in the final analysis and received either long-course nCRT plus TME with LLND or upfront TME+LLND. Groups were balanced by propensity score matching. The primary endpoint was 3-year recurrence-free survival (RFS).Findings: After matching, the nCRT group had significantly better 3-year RFS (HR 0.54; 95% CI. 0.32–0.92; P=0.023) and locoregional recurrence-free survival (HR 0.37; 95% CI, 0.19–0.74; P=0.005); distant metastasis-free survival did not differ (HR 0.74; 95% CI, 0.37–1.47; P=0.385). In patients with pretreatment positive lateral nodes (n=141), nCRT also improved RFS (HR 0.53; 95% CI, 0.28–0.99; P=0.049) and local control (HR 0.35; 95% CI, 0.15–0.77; P=0.010). Pathologic complete response in lateral nodes after nCRT was 44.7% (34/76). Overall postoperative complication rates were similar between groups (19.8% vs 16.0%; P=0.474), as were severe complications (grade III–V, 9.4% vs 8.5%; P=0.811).Interpretation: In MRI-suspected LLNM, adding nCRT to TME with LLND significantly improves RFS and local control without increasing morbidity. Upfront surgery alone is insufficient. These findings support a combined treatment paradigm and confirm the necessity of nCRT in these patients.
- Open Access
- 5 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1746927
Beyond prediction: AI as a mechanistic microscope and digital twin for colorectal cancer immunotherapy
Colorectal cancer (CRC) remains a major cause of cancer-related death, yet the benefits of immune checkpoint inhibitors are limited to a small subset of patients, particularly those with microsatellite instability-high or mismatch repair-deficient tumors. Most patients with microsatellite-stable disease derive little benefit, and even responsive subgroups show substantial heterogeneity and acquired resistance. These challenges highlight the need for biomarkers and therapeutic frameworks that can not only predict response, but also explain underlying biology and support dynamic treatment decisions. In this review, we propose that artificial intelligence (AI) can move beyond prediction to serve two broader roles in CRC immunotherapy: as a mechanistic microscope that reveals hidden tumor–immune interactions from multimodal data, and as a digital twin that models patient-specific therapeutic trajectories over time. We summarize recent advances in AI-based pathology, imaging, and liquid biopsy for pretreatment stratification and response monitoring, and discuss how these approaches may inform resistance mapping, adaptive trial design, and strategies to convert immunologically “cold” tumors into “hot” tumors. We further examine key translational barriers, including generalizability, interpretability, and regulatory validation. By integrating multimodal data with mechanistic modeling, AI may help shift CRC immunotherapy from population-level prediction toward dynamic, individualized precision oncology.
- 5 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1746927
Open AccessBeyond prediction: AI as a mechanistic microscope and digital twin for colorectal cancer immunotherapy
Colorectal cancer (CRC) remains a major cause of cancer-related death, yet the benefits of immune checkpoint inhibitors are limited to a small subset of patients, particularly those with microsatellite instability-high or mismatch repair-deficient tumors. Most patients with microsatellite-stable disease derive little benefit, and even responsive subgroups show substantial heterogeneity and acquired resistance. These challenges highlight the need for biomarkers and therapeutic frameworks that can not only predict response, but also explain underlying biology and support dynamic treatment decisions. In this review, we propose that artificial intelligence (AI) can move beyond prediction to serve two broader roles in CRC immunotherapy: as a mechanistic microscope that reveals hidden tumor–immune interactions from multimodal data, and as a digital twin that models patient-specific therapeutic trajectories over time. We summarize recent advances in AI-based pathology, imaging, and liquid biopsy for pretreatment stratification and response monitoring, and discuss how these approaches may inform resistance mapping, adaptive trial design, and strategies to convert immunologically “cold” tumors into “hot” tumors. We further examine key translational barriers, including generalizability, interpretability, and regulatory validation. By integrating multimodal data with mechanistic modeling, AI may help shift CRC immunotherapy from population-level prediction toward dynamic, individualized precision oncology.
- 21 April 2026
- Published by Taylor & Francis in Chronobiology International
- Vol. 43 (8) , 1-9
BMAL1 as a central chronobiological integrator of intestinal homeostasis, inflammation, and tumorigenesis
The biological clock gene BMAL1 (Brain and Muscle ARNT-like Protein 1) is a core regulator of circadian rhythms, orchestrating various physiological processes to maintain health. Recent studies demonstrate BMAL1's pivotal role in the digestive system, extending beyond traditional rhythmic regulation. BMAL1, a key transcription factor, forms heterodimers with CLOCK proteins to regulate the expression of genes involved in gastrointestinal motility, digestive enzyme secretion, and nutrient absorption. This review systematically explores BMAL1's multifaceted roles in digestive function, including its impact on gastrointestinal motility, digestive enzyme secretion, nutrient absorption, and its association with digestive diseases. We also discuss BMAL1's regulation of drug metabolism and its potential as a therapeutic target for circadian rhythm disorders. Understanding BMAL1's mechanisms provides new insights into the complex interplay between circadian rhythms, metabolism, and intestinal health, offering potential strategies for optimizing clinical treatments and reducing side effects.
- 21 April 2026
- Published by Taylor & Francis in Chronobiology International
- Vol. 43 (8) , 1-9
BMAL1 as a central chronobiological integrator of intestinal homeostasis, inflammation, and tumorigenesis
The biological clock gene BMAL1 (Brain and Muscle ARNT-like Protein 1) is a core regulator of circadian rhythms, orchestrating various physiological processes to maintain health. Recent studies demonstrate BMAL1's pivotal role in the digestive system, extending beyond traditional rhythmic regulation. BMAL1, a key transcription factor, forms heterodimers with CLOCK proteins to regulate the expression of genes involved in gastrointestinal motility, digestive enzyme secretion, and nutrient absorption. This review systematically explores BMAL1's multifaceted roles in digestive function, including its impact on gastrointestinal motility, digestive enzyme secretion, nutrient absorption, and its association with digestive diseases. We also discuss BMAL1's regulation of drug metabolism and its potential as a therapeutic target for circadian rhythm disorders. Understanding BMAL1's mechanisms provides new insights into the complex interplay between circadian rhythms, metabolism, and intestinal health, offering potential strategies for optimizing clinical treatments and reducing side effects.
- Open Access
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1674059
Case Report: Lumbar herniation of a low-grade appendiceal mucinous neoplasm mimicking a chronic abscess
Low-grade appendiceal mucinous neoplasms (LAMNs) are uncommon tumors that may lead to peritoneal dissemination if not completely excised, yet they often present with nonspecific symptoms. We describe a 53−year−old male with a three−year history of recurrent right lumbar “abscesses” whose contrast−enhanced CT suggested herniation of the ileocecal region into the abdominal wall. Laparoscopic exploration revealed a superior lumbar hernia containing an enlarged appendix with surrounding purulent fluid. The patient underwent laparoscopic ileocecal resection with side−to−side ileocolic anastomosis and drainage. Postoperative pathology confirmed a LAMN with surrounding suppurative changes and diverticular features in the right colon. No mesh repair was performed due to active inflammation; instead, staged hernia repair was planned. The patient recovered uneventfully, with no evidence of pseudomyxoma peritonei or hernia recurrence at follow−up. This case highlights the importance of considering appendiceal neoplasia in atypical hernias mimicking chronic abscesses, as timely recognition and complete oncologic resection are critical to prevent mucinous peritoneal spread and achieve optimal outcomes.
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1674059
Open AccessCase Report: Lumbar herniation of a low-grade appendiceal mucinous neoplasm mimicking a chronic abscess
Low-grade appendiceal mucinous neoplasms (LAMNs) are uncommon tumors that may lead to peritoneal dissemination if not completely excised, yet they often present with nonspecific symptoms. We describe a 53−year−old male with a three−year history of recurrent right lumbar “abscesses” whose contrast−enhanced CT suggested herniation of the ileocecal region into the abdominal wall. Laparoscopic exploration revealed a superior lumbar hernia containing an enlarged appendix with surrounding purulent fluid. The patient underwent laparoscopic ileocecal resection with side−to−side ileocolic anastomosis and drainage. Postoperative pathology confirmed a LAMN with surrounding suppurative changes and diverticular features in the right colon. No mesh repair was performed due to active inflammation; instead, staged hernia repair was planned. The patient recovered uneventfully, with no evidence of pseudomyxoma peritonei or hernia recurrence at follow−up. This case highlights the importance of considering appendiceal neoplasia in atypical hernias mimicking chronic abscesses, as timely recognition and complete oncologic resection are critical to prevent mucinous peritoneal spread and achieve optimal outcomes.
- Open Access
- 1 October 2025
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 80 (2) , 140-145
Intermittent vs. continuous: a comparative narrative review of enteral and parenteral nutrition support strategies in the perioperative setting
Enteral and parenteral nutrition are two primary methods of nutritional support in clinical settings. Their administration modes—continuous or intermittent—have garnered increasing attention in recent research. Continuous enteral and parenteral nutrition provide steady metabolic support over extended periods, particularly beneficial for critically ill patients or those with high nutritional demands. Conversely, intermittent feeding, delivered at scheduled intervals, simulates natural eating patterns and may offer advantages in gastrointestinal function and metabolic regulation. Recent studies indicate notable differences between continuous and intermittent feeding in perioperative patients, especially regarding metabolic control, gastrointestinal tolerance, immune function, and postoperative complications. Continuous feeding simplifies clinical management through stable nutrient delivery but may increase the risks of metabolic overload, liver dysfunction, and gastrointestinal intolerance. In contrast, intermittent feeding promotes recovery of gastrointestinal function and potentially reduces the risk of infections and other postoperative complications. This review aims to assess the clinical outcomes of continuous versus intermittent enteral and parenteral nutrition in perioperative patients, with a primary focus on gastrointestinal surgery populations (where gut-specific mechanisms are most critical). By evaluating these feeding strategies in terms of postoperative complications, recovery, metabolic regulation, and quality of life, we seek to provide evidence-based recommendations for optimizing perioperative nutritional care and improving patient outcomes.
- 1 October 2025
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 80 (2) , 140-145
Open AccessIntermittent vs. continuous: a comparative narrative review of enteral and parenteral nutrition support strategies in the perioperative setting
Enteral and parenteral nutrition are two primary methods of nutritional support in clinical settings. Their administration modes—continuous or intermittent—have garnered increasing attention in recent research. Continuous enteral and parenteral nutrition provide steady metabolic support over extended periods, particularly beneficial for critically ill patients or those with high nutritional demands. Conversely, intermittent feeding, delivered at scheduled intervals, simulates natural eating patterns and may offer advantages in gastrointestinal function and metabolic regulation. Recent studies indicate notable differences between continuous and intermittent feeding in perioperative patients, especially regarding metabolic control, gastrointestinal tolerance, immune function, and postoperative complications. Continuous feeding simplifies clinical management through stable nutrient delivery but may increase the risks of metabolic overload, liver dysfunction, and gastrointestinal intolerance. In contrast, intermittent feeding promotes recovery of gastrointestinal function and potentially reduces the risk of infections and other postoperative complications. This review aims to assess the clinical outcomes of continuous versus intermittent enteral and parenteral nutrition in perioperative patients, with a primary focus on gastrointestinal surgery populations (where gut-specific mechanisms are most critical). By evaluating these feeding strategies in terms of postoperative complications, recovery, metabolic regulation, and quality of life, we seek to provide evidence-based recommendations for optimizing perioperative nutritional care and improving patient outcomes.
- Open Access
- 6 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1591359
Unveiling the dual role of circulating tumor cells in colorectal cancer immunotherapy: a comprehensive review of biomarker utility and immune microenvironment crosstalk
Colorectal cancer (CRC) has the highest incidence in the Asia-Pacific region, accounting for 51.8% of global cases. Despite early screening methods like colonoscopy, CT, and MRI, 20-25% of patients are diagnosed at advanced stages, with some having liver metastasis. Personalized treatments, including targeted and immunotherapy, are crucial for metastatic or recurrent CRC. Circulating tumor cells (CTC), emerging as a non-invasive biomarker, play a key role in assessing metastasis and prognosis. CTC count is linked to CRC stage, microsatellite instability (MSI-H), and drug resistance, and is valuable in evaluating the response to immune checkpoint inhibitors (ICIs). Immune cells in the tumor microenvironment influence CTC behavior, impacting metastasis, immune evasion, and resistance. Advances in CTC detection and genetic markers offer new possibilities for early diagnosis and personalized treatment.
- 6 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1591359
Open AccessUnveiling the dual role of circulating tumor cells in colorectal cancer immunotherapy: a comprehensive review of biomarker utility and immune microenvironment crosstalk
Colorectal cancer (CRC) has the highest incidence in the Asia-Pacific region, accounting for 51.8% of global cases. Despite early screening methods like colonoscopy, CT, and MRI, 20-25% of patients are diagnosed at advanced stages, with some having liver metastasis. Personalized treatments, including targeted and immunotherapy, are crucial for metastatic or recurrent CRC. Circulating tumor cells (CTC), emerging as a non-invasive biomarker, play a key role in assessing metastasis and prognosis. CTC count is linked to CRC stage, microsatellite instability (MSI-H), and drug resistance, and is valuable in evaluating the response to immune checkpoint inhibitors (ICIs). Immune cells in the tumor microenvironment influence CTC behavior, impacting metastasis, immune evasion, and resistance. Advances in CTC detection and genetic markers offer new possibilities for early diagnosis and personalized treatment.
- Open Access
- 2 June 2025
- Published by Taylor & Francis in Gut Microbes
- Vol. 17 (1) , 2512010
Exploring the etiology of colitis: insights from gut microbiota research
Colitis represents a significant global health concern, with its incidence rising annually in recent years. Despite the unclear specifics of its pathogenic mechanisms, dysbiosis of the intestinal microbiota is recognized as a major factor contributing to various forms of colitis. This article examines the mechanisms through which alterations in intestinal microbiota contribute to the pathogenesis of several common types of colitis. These mechanisms predominantly involve disruption of barrier function, aberrant immune responses, and damage induced by microbial metabolites. This review offers insights that enhance the understanding of colitis pathogenesis.
- 2 June 2025
- Published by Taylor & Francis in Gut Microbes
- Vol. 17 (1) , 2512010
Open AccessExploring the etiology of colitis: insights from gut microbiota research
Colitis represents a significant global health concern, with its incidence rising annually in recent years. Despite the unclear specifics of its pathogenic mechanisms, dysbiosis of the intestinal microbiota is recognized as a major factor contributing to various forms of colitis. This article examines the mechanisms through which alterations in intestinal microbiota contribute to the pathogenesis of several common types of colitis. These mechanisms predominantly involve disruption of barrier function, aberrant immune responses, and damage induced by microbial metabolites. This review offers insights that enhance the understanding of colitis pathogenesis.